Glenmark has initiated phase 3 clinical trials in India on the use of generic antiviral drug Favipiravir for treatment of mild to moderate covid-19. Clinical trials have started and over 10 leading hospitals in India are enrolled for the study. Favipiravir is a generic version of Avigan manufactured by Fuji Chemicals of Japan. A number of companies are racing against time and it remains to be seen who gets the best of the opportunity. Patients with severe COVID-19 requiring ventilator support will not be included in the trials. Favipiravir has shown some early promise in treating mild to moderate COVID-19.